ヘルスケア
ヘルスケアは、グローバルトレンド、技術・革新及び各国の市場特性、人口動態や規制当局に影響を受けるセクターです。
アジアにおける投資及び業界再編に影響を与える主な要因は:
- 可処分所得の増加、急速に変化する多様な人口動態;
- 地理的及び生理学的な特性;
- 政府・行政支援による医療システムの発展;
- メディカル及びライフサイエンステクノロジーに精通するイノベーターの出現;
- 世界の成長市場に対する需要が拡大する中、アジアと欧米の間では、地域企業による双方向M&Aの動きが加速
当社のグローバル・ヘルスケアチームは、企業、金融スポンサー、起業家の皆様に対し、各地域に根ざした高度な知見とグローバルな視点、豊富な取引実績を融合させたアドバイザリーサービスを提供しています。
対応領域は、ヘルスケアサービス、医療機器、製薬・バイオテクノロジー、製薬業務のアウトソーシング(CRO・CDMO)、コンシューマーヘルス、アニマルヘルスおよび植物・生命科学など、多岐にわたります。

Andrew Huntley
Managing Partner, Head of Healthcare

Sanjay Singh
Partner, Head of BDA India, Co-Head Asia Healthcare

Sophia Wu
Managing Director, Head of Healthcare, China
invested in
a portfolio company of
2025
has divested strategic stake to
2025
divested majority stake in
to
2024
acquired majority stake in
2024
has been acquired by
2023
received investment from
2023
a subsidiary of
has acquired
2022
a portfolio company of
has been acquired by
2022
agreed to divest East Syracuse, New York facility to
2022
has sold minority stake to
2022
a portfolio company of
has been acquired by
2022
investment from
2021
has been acquired by
2021
a portfolio company of
has been acquired majority stake by
2021
a portfolio company of
has been acquired by
2021
divested majority stake to
DCP Capital
2021
agreed to divest Couvet, Switzerland facility to WuXi AppTec
2021
raised Series B round from
2021
backed by
has been acquired by
2020
divested Escientia Life Sciences to Deccan Fine Chemicals
2020
divested significant stake in
Kehua Bio-Engineering to Gree Real Estate
2020
majority sale
2019
LAP Lasers a portfolio company of
has been acquired by
2019
divested majority stake to
2019
a portfolio company of
has been acquired by
AGIC and Humanwell
2017
recapitalized majority by
2017
divested CMC Biologics to
2017
has been acquired by a Japanese chemicals & life science company
2016
acquired Adval Tech Medical (Suzhou) and Omni Manufacturing (Mexico)
2013
divested Radiant Research Inc, US-based clinical research company
2012